India’s new intellectual property rights (IPR) policy attempts to address concerns of developed countries regarding India’s patent regime, while also protecting public interest, especially that of generic drug producers. However, through this effort of a balancing act, India might have … Continue reading
April 27, 2016 – The United States Trade Representative’s (USTR) 2016 “Special 301 Report” was released yesterday. Many countries – including India – are targeted and put on a ‘Priority Watch List’ for using legal tools to protect generic competition … Continue reading
By Kritika Suneja, ET Bureau| April 27, 2016 NEW DELHI: India continues to figure in the US’ Priority Watch List that identifies trade barriers to US companies due to intellectual property laws of other countries.
BY WILLIAM NEW, INTELLECTUAL PROPERTY WATCH| April 27, 2016 The Office of the United States Trade Representative (USTR) does not hesitate to add even its closest friends to its annual list of concerns about possible inadequate protection of US intellectual … Continue reading
Source: Economic & Political Weekly| Vol. 51, Issue No. 12, 19 Mar, 2016 The Government of India gives “private assurances” to its friends in Big Pharma in the United States. The compulsory licence is the definitive instrument in the amended Patents … Continue reading
U.S. India Business Council (USIBC) in a submission to U.S. Trade Representatives (USTR) for the 2016 Special 301 Review has clearly stated “the Government of India has privately reassured it would not use Compulsory Licenses (CL) for commercial purposes.”; indicating … Continue reading
By Zeba Siddiqui, Reuters|March 9, 2016 India has given private assurances that it will not grant licences allowing local firms to override patents and make cheap copies of drugs by big Western drugmakers, a U.S. business advocacy group said.